{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:31:24Z","timestamp":1761823884766},"reference-count":26,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2000,8,16]]},"abstract":"<jats:p> PURPOSE: The combination of cisplatin, ifosfamide, and oral etoposide (PIEo) given concurrently with accelerated hyperfractionated thoracic radiation was studied in patients with limited small-cell lung cancer in a phase II trial to assess response, survival, and toxicity. <\/jats:p><jats:p> PATIENTS AND METHODS: Sixty-seven patients were accrued between March 1994 and April 1996. Chemotherapy doses were cisplatin 20 mg\/m<jats:sup>2<\/jats:sup> and ifosfamide 1,200 mg\/m<jats:sup>2<\/jats:sup> on days 1 to 3 and etoposide 40 mg\/m<jats:sup>2<\/jats:sup> administered orally days 1 through 14. Radiation consisted of accelerated hyperfractionated thoracic radiation (AHTRT) 1.5 Gy bid \u00d7 30 fractions (total 45 Gy) days 1 through 19, concurrent with cycle 1 of chemotherapy. Three additional cycles of chemotherapy were given every 4 weeks after completion of chemoradiation. Prophylactic cranial radiation (25 Gy in 10 fractions) was offered to patients for whom complete response (CR) after completion of chemotherapy was achieved. <\/jats:p><jats:p> RESULTS: An overall objective response rate of 78% (41 CRs [67%] and seven partial responses [11%]) was seen in 61 patients whose disease response could be evaluated. Median progression-free and overall survival estimates were 12.7 and 23.7 months, respectively. Two- and 3-year survival rates were estimated at 50% and 39%, respectively. Major toxic effects included grade 4 granulocytopenia in 34 (55%), grade 4 thrombocytopenia in 16 (26%), grade 3 to 5 fever\/infection in six (10%; with one death resulting from sepsis), and grade 3\/4 esophagitis in 27 patients (43%). Other nonhematologic toxic greater than grade 2 occurred in 11 patients (18%). <\/jats:p><jats:p> CONCLUSION: Relative to conventional etoposide\/cisplatin and concurrent AHTRT, chemoradiation with PIEo produced similar median and 2-year survival rates and a higher rate of acute esophageal toxicity. However, the locoregional control rate with a minimum follow-up of 2 years is excellent at 80%. It is conceivable that longer follow-up will prove this regimen more promising. Research efforts should focus on other methods to improve disease control in all potential sites of recurrence. <\/jats:p>","DOI":"10.1200\/jco.2000.18.16.2990","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T09:19:48Z","timestamp":1487927988000},"page":"2990-2995","source":"Crossref","is-referenced-by-count":28,"title":["Cisplatin, Ifosfamide, Oral Etoposide, and Concurrent Accelerated Hyperfractionated Thoracic Radiation for Patients With Limited Small-Cell Lung Carcinoma: Results of Radiation Therapy Oncology Group Trial 93-12"],"prefix":"10.1200","volume":"18","author":[{"given":"Bonnie","family":"Glisson","sequence":"first","affiliation":[{"name":"From the University of Texas M.D. Anderson Cancer CenterHouston, TX; Radiation Therapy Oncology Group and Fox Chase Cancer Center, Philadelphia, PA; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Scott","sequence":"additional","affiliation":[{"name":"From the University of Texas M.D. Anderson Cancer CenterHouston, TX; Radiation Therapy Oncology Group and Fox Chase Cancer Center, Philadelphia, PA; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuko","family":"Komaki","sequence":"additional","affiliation":[{"name":"From the University of Texas M.D. Anderson Cancer CenterHouston, TX; Radiation Therapy Oncology Group and Fox Chase Cancer Center, Philadelphia, PA; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Movsas","sequence":"additional","affiliation":[{"name":"From the University of Texas M.D. Anderson Cancer CenterHouston, TX; Radiation Therapy Oncology Group and Fox Chase Cancer Center, Philadelphia, PA; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Wagner","sequence":"additional","affiliation":[{"name":"From the University of Texas M.D. Anderson Cancer CenterHouston, TX; Radiation Therapy Oncology Group and Fox Chase Cancer Center, Philadelphia, PA; and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-0409","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199212033272302"},{"key":"R2-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.6.890"},{"key":"R3-0409","unstructured":"Goto  K,  Nishiwaki  Y,  Takada  M, et al:  Final results of a phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer:  The Japan Clinical Oncology Group Study. Proc Am Soc Clin Oncol 18:468a,1999  (abstr 1805)"},{"key":"R4-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.2.336"},{"key":"R5-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.893"},{"key":"R6-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.892"},{"key":"R7-0409","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(88)90364-1"},{"key":"R8-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.806"},{"key":"R9-0409","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400403"},{"key":"R10-0409","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<309::AID-CNCR9>3.0.CO;2-L"},{"key":"R11-0409","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00709-8"},{"key":"R12-0409","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"R13-0409","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R14-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1615"},{"key":"R15-0409","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920201)69:3<669::AID-CNCR2820690312>3.0.CO;2-V"},{"key":"R16-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.10.2594"},{"key":"R17-0409","doi-asserted-by":"crossref","unstructured":"Dombernowsky  P,  Nissen  NI:  Schedule dependence of the antileukaemic activity of the podophyllotoxin-derivative VP 16-213 (NSC 141540) in L1210 leukaemia.  Acta Path Microbiol Immunol Scan 81:715,1973\u2013724,","DOI":"10.1111\/j.1699-0463.1973.tb03564.x"},{"key":"R18-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.10.1613"},{"key":"R19-0409","unstructured":"Einhorn  LH,  Pennington  K,  McClean  J:  Phase II trial of daily oral VP-16 in refractory small cell lung cancer:  A Hoosier Oncology Group study. Semin Oncol 7:32,1990\u201335,"},{"key":"R20-0409","unstructured":"Clark  PI,  Joel  SP,  Thompson  PI, et al:  Prolonged administration of single-agent oral etoposide in patients with untreated small cell lung cancer (SCLC).  Proc Am Soc Clin Oncol 9:226,1990  (abstr 874)"},{"key":"R21-0409","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920115)69:2<370::AID-CNCR2820690217>3.0.CO;2-E"},{"key":"R22-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.8.1871"},{"key":"R23-0409","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1055"},{"key":"R24-0409","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00251-4"},{"key":"R25-0409","unstructured":"Sauer  R,  Wannenmarcher  M,  Wasserman  T, et al:  Randomized phase III trial of radiation \u00b1 amifostine in patients with head and neck cancer.  Proc Am Soc Clin Oncol 18:392a,1999  (abstr 1516)"},{"key":"R26-0409","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410703"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2000.18.16.2990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:00:45Z","timestamp":1653516045000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2000.18.16.2990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,16]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2000,8,16]]}},"alternative-id":["10.1200\/JCO.2000.18.16.2990"],"URL":"https:\/\/doi.org\/10.1200\/jco.2000.18.16.2990","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,8,16]]}}}